Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks

Authors

Judith A. Aberg, New York University School of MedicineFollow
Pablo Tebas, University of Pennsylvania School of Medicine
Edgar Turner Overton, Washington University School of Medicine in St. Louis
Samir K. Gupta, Indiana University School of Medicine
Paul E. Sax, Harvard Medical School
Alan Landay, Rush University Medical CenterFollow
Ron Falcon, Janssen Therapeutics
Robert Ryan, Janssen R&D
Guy De La Rosa, Janssen Global Services

Journal

AIDS Research and Human Retroviruses

Publication Date

9-20-2012

Volume

28

Issue

10

Inclusive Pages

1184-1195

Document Type

Open Access Publication

DOI

10.1089/aid.2011.0327

Rights and Permissions

Judith A. Aberg, Pablo Tebas, Edgar Turner Overton, Samir K. Gupta, Paul E. Sax, Alan Landay, Ron Falcon, Robert Ryan, and Guy De La Rosa. AIDS Research and Human Retroviruses. October 2012, 28(10): 1184-1195. doi:10.1089/aid.2011.0327.

Recommended Citation

Aberg, Judith A.; Tebas, Pablo; Overton, Edgar Turner; Gupta, Samir K.; Sax, Paul E.; Landay, Alan; Falcon, Ron; Ryan, Robert; and De La Rosa, Guy, "Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks." AIDS Research and Human Retroviruses. 28, 10. 1184-1195. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/2729